Clinical Dilemmas in Viral Liver Disease

by Foster, Graham R   Reddy, K. Rajender
2020

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection

by Naganuma, Atsushi   Chayama, Kazuaki   Notsumata, Kazuo   Gane, Edward   Foster, Graham R   Wyles, David   Kwo, Paul   Crown, Eric   Bhagat, Abhi   Mensa, Federico J   Otani, Tetsuya   Larsen, Lois   Burroughs, Margaret   Kumada, Hiromitsu Published in Journal of gastroenterology (05.08.2019)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale‐up in the age of direct‐acting antivirals

by Martin, Natasha K   Vickerman, Peter   Grebely, Jason   Hellard, Margaret   Hutchinson, Sharon J   Lima, Viviane D   Foster, Graham R   Dillon, John F   Goldberg, David J   Dore, Gregory J   Hickman, Matthew Published in Hepatology (Baltimore, Md.) (01.11.2013)

Interferons at age 50: past, current and future impact on biomedicine

by Silverman, Robert H   Borden, Ernest C   Sen, Ganes C   Foster, Graham R   Uze, Gilles   Ransohoff, Richard M   Stark, George R Published in Nature reviews. Drug discovery (01.12.2007)

Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

by Martin, Natasha K   Vickerman, Peter   Miners, Alec   Foster, Graham R   Hutchinson, Sharon J   Goldberg, David J   Hickman, Matthew Published in Hepatology (Baltimore, Md.) (01.01.2012)

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

by Zeuzem, Stefan   Foster, Graham R   Wang, Stanley   Asatryan, Armen   Gane, Edward   Feld, Jordan J   Asselah, Tarik   Bourlière, Marc   Ruane, Peter J   Wedemeyer, Heiner   Pol, Stanislas   Flisiak, Robert   Poordad, Fred   Chuang, Wan-Long   Stedman, Catherine A   Flamm, Steven   Kwo, Paul   Dore, Gregory J   Sepulveda-Arzola, Gladys   Roberts, Stuart K   Soto-Malave, Ruth   Kaita, Kelly   Puoti, Massimo   Vierling, John   Tam, Edward   Vargas, Hugo E   Bruck, Rafi   Fuster, Francisco   Paik, Seung-Woon   Felizarta, Franco   Kort, Jens   Fu, Bo   Liu, Ran   Ng, Teresa I   Pilot-Matias, Tami   Lin, Chih-Wei   Trinh, Roger   Mensa, Federico J Published in The New England journal of medicine (25.01.2018)

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

by Puoti, Massimo   Foster, Graham R   Wang, Stanley   Mutimer, David   Gane, Edward   Moreno, Christophe   Chang, Ting Tsung   Lee, Samuel S   Marinho, Rui   Dufour, Jean-Francois   Pol, Stanislas   Hezode, Christophe   Gordon, Stuart C   Strasser, Simone I   Thuluvath, Paul J   Zhang, Zhenzhen   Lovell, Sandra   Pilot-Matias, Tami   Mensa, Federico J Published in Journal of hepatology (01.08.2018)

Corrigendum to “Second generation direct-acting antivirals – do we expect major improvements?”

by Feld, Jordan J   Foster, Graham R Published in Journal of hepatology (2017)

Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

by Rivino, Laura   Le Bert, Nina   Gill, Upkar S   Kunasegaran, Kamini   Cheng, Yang   Tan, Damien Zm   Becht, Etienne   Hansi, Navjyot K   Foster, Graham R   Su, Tung-Hung   Tseng, Tai-Chung   Lim, Seng Gee   Kao, Jia-Horng   Newell, Evan W   Kennedy, Patrick Tf   Bertoletti, Antonio Published in The Journal of clinical investigation (01.02.2018)

O4 Amino acid substitution in genotype 3a hepatitis C virus polymerase protein affects responses to sofosbuvir and interferon alpha and inhibits apoptosis

by Lee, Wing-yiu Jason   Jones, Meleri   Wing, Peter AC   Rajagopal, Swathi   Foster, Graham R Published in Gut (01.09.2020)